EP Patent

EP3545949A1 — Oral dosage forms comprising pomalidomide crystalline form a

Assigned to Midas Pharma GmbH · Expires 2019-10-02 · 7y expired

What this patent protects

The invention relates to oral pharmaceutical compositions comprising Pomalidomide crystalline form A and a stabilizer being selected from sucrose, lactitol, maltitol and mixtures thereof.

USPTO Abstract

The invention relates to oral pharmaceutical compositions comprising Pomalidomide crystalline form A and a stabilizer being selected from sucrose, lactitol, maltitol and mixtures thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3545949A1
Jurisdiction
EP
Classification
—
Expires
2019-10-02
Drug substance claim
No
Drug product claim
No
Assignee
Midas Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.